High grade glioma no ehfr.no cdkn2a. Non infiltrante. With yp53 and tert

TL;DR:

Your tumor has specific genetic markers (TP53 and TERT mutations) that your doctors will use to guide treatment decisions—this information helps them choose the most effective approach for your particular cancer.

KEY POINTS:

• High-grade glioma means this is an aggressive brain tumor that grows quickly and needs prompt treatment
• No EGFR, no CDKN2A means certain targeted therapy options may not apply to your tumor, which actually narrows down what your doctors will recommend
• TP53 and TERT mutations are genetic changes found in your tumor cells that provide important clues about how it behaves and what treatments may work best
• Non-infiltrative (if that's what "non infiltrante" means) is potentially favorable—it suggests the tumor may have clearer boundaries, which could affect surgery planning
• These molecular markers help your oncology team personalize your treatment plan rather than using a one-size-fits-all approach

NEXT STEP:

Ask your neuro-oncologist to explain which treatment options (surgery, radiation, chemotherapy, or clinical trials) they're recommending based on these specific genetic findings.

---

[[FULL_ANSWER]]

Understanding Your Tumor's Genetic Profile

You've received important molecular information about your high-grade glioma. Let me break down what each of these findings means in practical terms.

What is a High-Grade Glioma?

A glioma is a brain tumor that starts in glial cells (support cells in the brain). "High-grade" means the tumor cells look very abnormal under the microscope and grow quickly. According to the Musella Foundation's Brain Tumor Guide for the Newly Diagnosed, high-grade gliomas require urgent treatment planning because they tend to be aggressive.

What Do These Genetic Markers Mean?

Your pathology report mentions several important molecular findings:

EGFR: Negative (No EGFR mutation)

• EGFR is a protein that some brain tumors overuse to grow faster
• The fact that your tumor does NOT have this mutation means certain targeted drugs (like erlotinib or gefitinib) may not be effective for you
• This actually helps your doctors narrow down which treatments to focus on

CDKN2A: Negative (No CDKN2A deletion)

• CDKN2A is a tumor-suppressor gene (a "brake" on cell growth)
• When this gene is deleted in gliomas, it often means more aggressive behavior
• Your tumor does NOT have this deletion, which is a more favorable finding

TP53 Mutation: Present

• TP53 is another critical tumor-suppressor gene—sometimes called the "guardian of the genome"
• When TP53 is mutated, cells lose an important safety mechanism that normally stops them from becoming cancerous
• TP53 mutations are common in high-grade gliomas and suggest the tumor may be more aggressive
• This finding helps your doctors understand your tumor's biology and may influence treatment selection

TERT Mutation: Present

• TERT controls telomerase, an enzyme that allows cells to divide indefinitely
• TERT mutations in brain tumors are associated with increased cell division and tumor growth
• This is another marker that helps explain why your tumor is behaving aggressively
• Combined with TP53, this suggests your tumor has multiple genetic "hits" that make it more dangerous

What Does "Non-Infiltrative" Mean?

If your tumor is described as non-infiltrative (or non-infiltrating), this suggests the tumor has relatively clear boundaries rather than spreading diffusely into surrounding brain tissue. This can be favorable for surgery planning because it may mean your neurosurgeon can remove more of the tumor while preserving healthy brain tissue.

How Doctors Use This Information

According to the Musella Foundation's Brain Tumor Guide, molecular markers like these help oncologists make personalized treatment decisions. Here's how:

1. Surgery Planning: Your neurosurgeon will use imaging and these molecular findings to plan the safest and most complete tumor removal possible

2. Radiation Therapy: High-grade gliomas typically receive radiation after surgery. Your molecular profile helps determine the dose and technique

3. Chemotherapy Selection: Temozolomide (Temodar) is standard chemotherapy for high-grade gliomas. Your molecular markers help your team decide if additional chemotherapy drugs should be added

4. Clinical Trial Eligibility: Your specific genetic profile may make you eligible for clinical trials testing newer immunotherapies or targeted treatments designed for tumors with TP53 and TERT mutations

Standard Treatment Approach for High-Grade Glioma

The Musella Foundation's Brain Tumor Guide describes the typical treatment sequence:

• Surgery: Maximum safe resection (removal) of the tumor
• Radiation Therapy: Usually 6 weeks of daily treatments
• Chemotherapy: Often temozolomide during and after radiation
• Ongoing Monitoring: Regular MRI scans to watch for recurrence

Your specific molecular findings may modify this standard approach, which is why discussing these results with your neuro-oncology team is critical.

Questions to Ask Your Oncology Team

1. Based on my TP53 and TERT mutations, which treatment approach do you recommend, and why?
2. Are there clinical trials available for patients with my specific genetic profile?
3. How does the absence of EGFR and CDKN2A mutations change your treatment recommendations?
4. What does "non-infiltrative" mean for my surgery and overall prognosis?
5. How will you monitor my response to treatment, and what imaging will you use?
6. Are there any newer immunotherapy options I should know about?

Where to Find More Information

The Musella Foundation (virtualtrials.org) maintains an extensive database of clinical trials specifically for brain tumor patients and provides detailed information about treatment options. The National Cancer Institute (cancer.gov) also has comprehensive information about gliomas and current research.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.